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Abstract
Rationale—The vascular adventitia is a complex layer of the vessel wall consisting of vasa 
vasorum microvessels, nerves, fibroblasts, immune cells, and resident progenitor cells. Adventitial 
progenitors express the stem cell markers, Sca1 and CD34 (AdvSca1 cells), have the potential to 
differentiate in vitro into multiple lineages, and potentially contribute to intimal lesions in vivo.
Objective—While emerging data support the existence of AdvSca1 cells, the goal of this study 
was to determine their origin, degree of multipotency and/or heterogeneity, and contribution to 
vessel remodeling.
Methods and Results—Using two in vivo fate-mapping approaches combined with a smooth 
muscle cell (SMC) epigenetic lineage mark, we report that a subpopulation of AdvSca1 cells is 
generated in situ from differentiated SMCs. Our data establish that the vascular adventitia contains 
phenotypically distinct subpopulations of progenitor cells expressing SMC, myeloid, and 
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hematopoietic progenitor-like properties and that differentiated SMCs are a source to varying 
degrees of each subpopulation. SMC-derived AdvSca1 cells exhibit a multipotent phenotype 
capable of differentiating in vivo into mature SMCs, resident macrophages, and endothelial-like 
cells. Following vascular injury, SMC-derived AdvSca1 cells expand in number and are major 
contributors to adventitial remodeling. Induction of the transcription factor Klf4 in differentiated 
SMCs is essential for SMC reprogramming in vivo while in vitro approaches demonstrate that 
Klf4 is essential for maintenance of the AdvSca1 progenitor phenotype.
Conclusions—We propose that generation of resident vascular progenitor cells from 
differentiated SMCs is a normal physiological process that contributes to the vascular stem cell 
pool and plays important roles in arterial homeostasis and disease.
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Smooth muscle cells; Kruppel-like factor 4; reprogramming; vascular biology; progenitor cell; 
adventitia; vascular remodeling
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INTRODUCTION
The static arrangement of concentric layers of intima, media, and adventitia found in most 
blood vessels fails to capture the dynamics of cell movement between the individual layers. 
Most studies that address this question have focused on migration of smooth muscle cells 
(SMCs) into the intimal layer, where cells from the circulation and from the vessel wall 
interact during progression of atherosclerotic plaques1. Little, if any, attention has been paid 
to the possibility that SMCs may also move in the opposite direction, into the adventitia. In 
part, this is due to the prevailing notion that the adventitia is an inert bystander tissue whose 
function is to provide structural support for the artery wall in the form of collagen-rich 
matrix produced by adventitial fibroblasts. However, this notion is challenged by recent 
studies showing that the adventitia actually contains a highly dynamic population of 
leukocytes, microvessels, adipocytes and resident progenitor cells that collectively both 
maintain the artery wall and respond robustly to many kinds of vascular injury2–5. In some 
cases, the adventitia is even the main site of pathological change such as in the formation of 
tertiary lymphoid organs in diseased arteries, fibrotic changes that reduce compliance and 
promote renal damage in hypertension, and as a focus for inflammatory cell accumulation in 
development of medial dissections and aneurysms6–9. In smaller vessels, the adventitia and 
associated perivascular cells are important signaling niches for resident progenitor cells in 
skeletal muscle10, kidney11, and bone marrow hematopoietic stem cells12. The perivascular 
niche is also a residence site for dormant cancer cells with metastatic potential13. Thus, 
factors governing the cell composition of the adventitia are important to identify for the 
health and maintenance of blood vessels and the tissues and stem cell populations they 
support.
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In recent years, reports demonstrating the existence of resident cardiovascular progenitor 
cells have had profound effects on our understanding of cardiovascular biology and tissue 
regeneration14–23. Emerging data suggest that several distinct progenitor populations with 
the capacity to differentiate into endothelial cells, smooth muscle cells (SMCs), fibroblasts, 
and macrophages reside in a specialized niche in the adventitia at the media-adventitia 
border. Hu, et.al.2 described a population of vascular progenitor cells in the aortic root 
adventitia of ApoE−/− mice that express the progenitor markers Sca1 and CD34 and 
differentiate to vascular SMCs in vitro (AdvSca1 progenitors). Our group showed similar 
cells cluster in an adventitial domain of sonic hedgehog (Shh) signaling, and while SMC 
marker negative, were found to express transcription factors known to activate SMC markers 
(e.g. serum response factor [SRF] and myocardin)4. They also express high levels of SRF 
co-repressors (eg. KLF4) suggesting AdvSca1(+) progenitors are specified for the SMC fate, 
but transcriptional repression maintains their progenitor phenotype. AdvSca1 progenitors 
were shown to have the potential to self renew or to differentiate in vitro into SMCs, 
endothelial cells, osteoblasts, chondrocytes, or adipocytes4, 24. These cells are not unique to 
murine vessels as adventitial-derived CD34(+) progenitor cells have also been isolated from 
human vessels14, 25. In addition, an intriguing finding was the existence of local, resident 
AdvSca1 myeloid progenitors with hematopoietic potential that reside in a similar 
adventitial niche5, 26. The presence of resident vascular progenitor cells has significant 
implications for their potential therapeutic use in the treatment of vascular diseases and 
regenerative medicine. While accumulating evidence supports their existence, a number of 
important questions remain unanswered. Several groups2, 5, 24 demonstrated that these cells 
do not originate from bone marrow and our previous findings4 demonstrated that adventitial 
progenitors do not arise from cardiac neural crest. Therefore, the origin of AdvSca1 
progenitor cells remains unclear. In addition, the degree of heterogeneity of AdvSca1 
progenitors and the mechanism underlying maintenance of the AdvSca1 progenitor cell 
phenotype are also unclear.
Vascular SMCs are specialized cells that express high levels of SMC-specific proteins, such 
as smooth muscle myosin heavy chain (Myh11/SMMHC) and smooth muscle-α-actin 
(Acta2/αSMC)27. Under pathological conditions, such as atherosclerosis and restenosis, 
however SMCs are capable of undergoing phenotypic and functional changes resulting in a 
proliferative, inflammatory phenotype characterized by decreased expression of SMC 
contractile proteins and increased production of pro-inflammatory cytokines. As a result, 
mature SMCs are major contributors to pathological neointima formation28–32. Our previous 
report using a highly specific SMC fate-mapping approach in the setting of restenosis 
demonstrated that the majority of proliferating intimal cells derive from mature SMCs33. 
Remarkably, we also consistently detected reporter-positive, but SMC marker-negative 
SMC-derived cells in the arterial adventitia, suggesting that mature SMCs contribute to both 
intimal and adventitial remodeling. In addition, recent reports demonstrated that a high 
percentage of SMCs in atherosclerotic lesions lack detectable expression of conventional 
SMC markers, but exhibit a macrophage-like phenotype3134, 35. These findings suggest that 
SMCs exhibit an even greater degree of plasticity than previously recognized. In light of our 
findings that SMCs contribute to adventitial remodeling and since the origin of AdvSca1 
progenitor cells remains unknown, we sought to determine if mature SMCs contribute to the 
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vascular progenitor pool. Using fate mapping and lineage tracing approaches, in this report 
we demonstrate that a distinct subpopulation of AdvSca1 progenitors derive from 
differentiated SMCs that undergo a reprogramming-like process in situ to generate 
multipotent progenitor cells. In addition, we show here that the pluripotency-associated 
transcription factor, Klf4, regulates the generation of SMC-derived AdvSca1 cells and is 
essential for the maintenance of the AdvSca1 progenitor cell phenotype.
METHODS
Mice
Myh11-CreERT2 transgenic mice and Rosa26-LacZ or Rosa26-YFP reporter mice were bred 
to generate tamoxifen-inducible SMC-specific β-galactosidase- or YFP-expressing mice 
(Myh11-CreERT-βGal/YFP). To activate Cre, adult male mice received 1-mg IP tamoxifen 
injections for 5 consecutive days 8 weeks before they were sacrificed. Timed pregnant 
females (Rosa26-YFP females bred to male Myh11-CreERT-Rosa26-YFP mice) received 1-
mg IP tamoxifen injections at e15 and e16 to label developing embryos. SM22α-Cre 
transgenic mice were bred to Rosa26-YFP to generate SMC-specific YFP-expressing mice 
(SM22α-Cre-YFP). For in vivo Matrigel™ plug assays, SMC-derived AdvSca1 cells were 
isolated as described below, resuspended in 700 μl Matrigel™ plus 100ng/ml VEGF and 
100ng/ml FGF2, and injected subcutaneously into wild type C57BL/6 recipients. Plugs were 
harvested 14 days post-injection, fixed in 4% buffered PFA, and embedded in OCT for 
immunofluorescent staining. To induce vascular injury, mice were subjected to wire-induced 
femoral artery injury or carotid artery ligation injury, as previously demonstrated33, 36. Four 
weeks after femoral artery injury or three days following carotid artery ligation injury, 
uninjured and injured arteries were harvested, perfusion fixed in 4% buffered PFA, and 
embedded in OCT for immunofluorescent staining. SM22α-CreKI transgenic mice 
(Taglntm2(cre)Yec; JAX stock 006878) were bred to Klf4 floxed mice and Rosa26-YFP mice 
to generate SMC-specific YFP-expressing Klf4-deficient mice (SM22α-CreKI-YFP KO). 
This alternative SMC Cre driver, in which Cre recombinase is activated very late in 
development compared to the traditional SM22α-Cre mouse line (TagIn-Cre; JAX stock 
004746), was used to generate SMC-specific Klf4 KO mice as use of TagIn-Cre mice 
resulted in embryonic lethality. Mice were maintained in the Center for Comparative 
Medicine, and procedures were performed under a protocol approved by the Institutional 
Animal Care and Use Committee at the University of Colorado Denver.
Cell analysis
Isolated aortic arch plus left and right carotid arteries, descending aortas, and left and right 
femoral arteries were digested to single cells by digestion at 37°C for 1hr in collagenase 
buffer. For flow sorting, single cell suspensions were incubated with a rat anti-mouse 
monoclonal APC-Sca1 antibody (eBiosciences); live cells were sorted on a MoFlo high-
speed cell sorter based on Sca1-APC and endogenous YFP expression. For FACS analysis, 
single cell suspensions were stained with various combinations of rat anti-mouse 
monoclonal antibodies (PerCP-Cy5.5-Sca1, PE-Cy7-CD45, APC/e780-Ly6C, PE-Cy7-
CD115, APC-CD140a, APC-CD140b, PE-CD31; all antibodies were from eBiosciences). 
Flow cytometry was performed on a Galios cytometer (Becton Dickenson). Data were 
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analyzed using Kaluza Software (Beckman Coulter). To quantitate AdvSca1 populations in 
WT versus SMC-specific Klf4 KO mice, vessels from 8–10-day old mice were individually 
digested to single cell suspensions, labeled with anti-APC-Sca1 antibodies, and analyzed for 
endogenous YFP and Sca1-APC expression. To analyze the effect of Klf4 on maintenance of 
the AdvSca1 progenitor cell phenotype, AdvSca1 cells were sorted based on Sca1 
expression, transfected with non-targeting or Klf4-targeting siGENOME SMARTpool 
siRNAs (100 nm; Thermo Scientific) or transduced with an empty vector adenovirus or an 
adenovirus expressing Klf4 (100 MOI; Vector Bioloabs, Malvern, PA).
Immunofluorescence, Chromatin Immunoprecipitation, and Quantitative RT-PCR
OCT-embedded tissues or fixed cells were permeabilized with MeOH followed by 0.05% 
Tween-20 in PBS, blocked in 3% horse serum, and sequentially incubated with specific 
primary and secondary antibodies. Antibodies used include monoclonal rat anti-mouse Sca1 
(1:100; BD Pharmingen), monoclonal rat anti-mouse CD34 (1:50; Abcam), FITC-
conjugated polyclonal goat anti-GFP (1:200; Abcam), Cy3-conjugated monoclonal anti-
smooth muscle alpha actin (αSMA; 1:2000; Sigma), monoclonal rat anti-mouse CD45 
(1:100; BD Pharmingen), polyclonal rabbit anti-Klf4 (1:100; Abcam), monoclonal rat anti-
mouse F4/80 (1:50; Abcam), polyclonal rabbit anti- smooth muscle alpha actin (αSMA; 
1:200; Abcam), and polyclonal rabbit anti-SMMHC (1:100; Biomedical Technologies, Inc.). 
Sections/cells were imaged using a laser-scanning confocal microscope (LSM 780 spectral, 
Carl Zeiss, Thornwood, NY). Tissues were stained for LacZ activity using a kit from GTS, 
Inc. according to the protocols provided. To quantitate cell populations in uninjured 
compared to injured carotid arteries, total numbers of Sca1 or CD45(−) YFP(+), Sca1 or 
CD45(+) YFP(+), and Sca1 or CD45(+) YFP(−) adventitial cells were counted in three high-
powered fields per vessel from n=3 uninjured and injured vessels by two independent 
investigators. Chromatin Immunoprecipitation (ChIP) was performed on flow-isolated cell 
populations as previously described37. Antibodies for ChiP include anti-H3K4Me2, anti-H4-
Ac (Millipore), and anti-SRF (Santa Cruz Biotechnologies). DNA was purified with 
QIAquick PCR purification kits (Qiagen). Real-time PCR with Power SYBR Green 
mastermix (Life Technologies) and primers designed to flank CaRG elements in the Acta2 
and Myh11 was used to analyze chromatin immunoprecipitation (primer sequences are 
available in the online Supplement). Data from a minimum of 3 independent experiments 
were normalized to YFP+ SMCs. Quantitative RT-PCR (qPCR) was used with total RNA 
isolated from flow-isolated cell populations as previously described33. Primer sequences are 
available in the online Supplement. β-actin was used for normalization. To compare among 
individual experiments, data was normalized to YFP+ SMCs for SMC genes (αSMA, 
SMMHC, SM22α, and myocardin) or AdvSca1-MA cells for progenitor cell genes (Klf4, 
CD34, VEGF, SDF-1α, CD31, Flk1, Flt1).
RESULTS
Genetic fate-mapping reveals adventitial SMC-derived progenitor cells
We previously used tamoxifen (tmx)-inducible Myh11CreERT2 transgenic mice crossed with 
floxed-stop ROSA reporter mice (Myh11-CreER-βGal/YFP) to fate map mature SMCs in 
response to vascular injury33. Tmx given to adult mice before vascular injury genetically, 
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permanently, and efficiently marked only Myh11/SMMHC-expressing SMCs through Cre-
mediated reporter knock-in. Since tmx was given before injury and then stopped, SMCs 
expressing Myh11/SMMHC and their progeny were the only reporter-positive cells 
throughout the experimental time period allowing tracking of mature SMCs in response to 
vascular injury even if levels of Myh11/SMMHC (or other SMC markers) were no longer 
detectable; any non-SMC that potentially gained expression of Myh11/SMMHC after injury 
would not be labeled as tmx was not in the system to activate Cre. Using this approach, we 
found that the majority of intimal Acta2/αSMA-expressing cells originate from mature 
SMCs (33 and Supplemental Figure I), establishing that neointimal SMCs derive from 
mature differentiated SMCs. However, similar to a recent report in the setting of 
atherosclerosis33, we also detected populations of YFP(+) SMC-derived intimal cells that 
expressed no detectable levels of SM markers (asterisks in Supplemental Figure 1) 
suggesting that the contribution of SMCs to intimal hyperplasia is underestimated if solely 
using expression of conventional SMC marker proteins to identify intimal SMCs. Mice not 
treated with tamoxifen exhibited no genetic labeling of SMCs or adventitial cells 
(Supplemental Figure II). In addition to intimal SMCs, we made the entirely unanticipated 
observation that over time mature SMCs migrate to the adventitia and reside in a niche at the 
adventitia-media border (33 and Figure 1A). Adventitial SMC-derived cells have lost SMC 
marker expression (Figure 1B&F, Acta2/αSMA shown), but gained expression of the stem 
cell markers, Sca1 and CD34 (Figure 1C,D,E,G) suggesting that differentiated SMCs 
generate AdvSca1 cells to contribute to the resident vascular progenitor cell pool.
Our previous report demonstrated that AdvSca1 progenitors appear in the adventitia of the 
ascending aorta and pulmonary trunk by e18.5, a developmental time point after the arterial 
media has acquired its complement of SMCs and has organized structured elastic lamellae4. 
Based on this, we hypothesized that SMC-derived AdvSca1 progenitors are established 
during the late embryonic-to-early postnatal period. To test this hypothesis, tmx was 
administered to timed-pregnant females at e15 and e16 to obtain restricted labeling of 
Myh11-expressing SMCs in embryos between e15 and e17, when all vascular beds exhibit 
strong Myh11/SMMHC expression and before the appearance of AdvSca1 cells. Pups were 
allowed to develop to 30 dpp, then carotid arteries plus aortic arch, descending aortas, and 
femoral arteries were harvested, digested into single cells, immuno-labeled for Sca1, and 
flow sorted based on Sca1 and YFP expression (gating strategy shown in Supplemental 
Figure III). Three distinct cell populations were retrieved from each vessel: (A) 
Sca1(−)YFP(+): mature SMCs; (B) Sca1(+)YFP(−): non-SMC-derived AdvSca1(+) cells 
(hereafter referred to as AdvSca1-MA); (C) Sca1(+)YFP(+): SMC-derived AdvSca1(+) cells 
(hereafter referred to as AdvSca1-SM) (Supplemental Figure IVA&B). Using this approach, 
we found approximately 8% of the total Sca1(+) cell population were YFP-positive SMC-
derived cells (Supplemental Figure IVB). In contrast to blood vessels, AdvSca1-SM cells 
were not detected in peripheral blood mononuclear cells (not shown). This is consistent with 
our previous finding of a lack of labeled cells in bone marrow33 and a previous report using 
a comparable SMC-specific labeling approach in which labeled cells were not detected in 
bone marrow cells or the circulation34. Others have used a similar in utero tamoxifen pulse 
to fate-map yolk sac-derived myeloid progenitors38 and hemogenic endothelial cells39, albeit 
tamoxifen was administered at much earlier developmental time points (e. g. e8.5). In 
Majesky et al. Page 6
Circ Res. Author manuscript; available in PMC 2018 January 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
contrast to these studies upon further examination in our system, while 5-d tmx treatment of 
adult mice resulted in highly efficient labeling of medial SMCs33, we were unable to achieve 
similar labeling delivering tmx in utero at these later time points (2 injections failed to 
efficiently label outer medial SMCs [Supplemental Figure IVC] and >2 in utero injections 
consistently resulted in premature termination of pregnancy) thus precluding the ability to 
accurately quantitate the percentage of AdvSca1 progenitors that originate from SMCs due 
to lack of genetic labeling. Nonetheless, using a highly selective fate-mapping approach, our 
data demonstrate that a population of resident AdvSca1 cells derives from mature SMCs.
In order to accurately quantitate the percentage of AdvSca1 cells that originate from SMCs, 
constitutive, SMC-specific SM22α-Cre transgenic mice were bred to ROSA26-YFP mice 
(SM22α-Cre-YFP) to label differentiating SMCs at the time in vascular development that 
SM22α is induced. We previously showed that AdvSca1 cells do not express SM22α4. 
Using this approach, we consistently found that a large percentage of total Sca1(+) cells in 
the carotid artery plus aortic arch, descending aorta, and femoral artery originate from SMCs 
(Figure 2A and Supplemental Figure V). By immunofluorescent staining, αSMA(−), but 
YFP(+)Sca1(+)CD34(+) cells were detected in the adventitia of 30d SM22α-Cre-YFP mice 
(Figure 2B&C). Consistent with in vivo staining, freshly isolated AdvSca1-SM cells from 
30d SM22α-Cre-YFP mice express high levels of progenitor cell markers, including Sca1, 
CD34, and the pluripotency-associated transcription factor, Klf4, but very dim to 
undetectable levels of αSMA (Supplemental Figure VI). To further strengthen that SMCs 
migrate into the adventitia and to provide evidence of the late developmental timing of SMC 
reprogramming, we analyzed arteries from 5-day old SM22α-Cre-YFP mice and detected 
Sca1(+)YFP(+) adventitial cells still expressing residual SMC markers (Figure 2D). Specific 
chromatin modifications occur selectively in SMC gene loci of SM markers (eg. Acta2/
αSMA, Myh11/SMMHC) and are associated with specification of the SMC lineage during 
development40, 41. Unlike most which are lost from SMC genes in response to SMC 
phenotypic switching (eg. H4Ac), one chromatin mark in particular, H3K4 dimethylation 
(H3K4Me2), is retained and serves as a highly specific SMC lineage marker in both mouse 
and human tissues40, 42. As a secondary approach to demonstrate SMC origin of 
YFP(+)Sca1(+) AdvSca1 cells, chromatin immunoprecipitation (ChIP) was conducted for 
expression of the H3K4Me2 mark in the Myh11 and Acta2 loci of isolated YFP(+)Sca1(+) 
compared to YFP(−)Sca1(+) cells. Similar to SMC-rich intact aortic media (not shown), 
H3K4Me2 was detected on the Myh11/SMMHC and Acta2/αSMA promoters of isolated 
YFP(+) mature SMCs and YFP(+)Sca1(+) AdvSca1-SM cells, but not YFP(−)Sca1(+) 
AdvSca1-MA cells (Supplemental Figure VIIA). In contrast, compared to mature YFP(+) 
SMCs, expression of the SMC differentiation-associated H4Ac chromatin mark40 was 
undetectable in YFP(+)Sca1(+) AdvSca1-SM cells (Supplemental Figure VIIB left; Myh11 
shown). Binding of the transcription factor, SRF, to CArG boxes of SM gene promoters is 
essential for promoting the SMC differentiation program40. Loss of the SMC differentiation 
H4Ac chromatin mark was associated with undetectable SRF binding to SM gene promoters 
in YFP(+)Sca1(+) AdvSca1-SM cells (Supplemental Figure VIIB right; Myh11 shown). 
Collectively, using two independent genetic fate-mapping systems combined with a SMC 
lineage histone mark, we established that differentiated SMCs generate in situ a 
subpopulation of AdvSca1 progenitor cells.
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Differentiated SMCs generate phenotypically distinct subpopulations of AdvSca1 cells
We used quantitative RT-PCR (qPCR) to further characterize individual cell populations. 
Mature SMCs, AdvSca1-SM progenitors, and AdvSca1-MA progenitors were isolated by 
flow sorting as described above. Compared to mature YFP(+)Sca1(−) SMCs, expression of 
the SMC-specific mRNAs, Myh11/SMMHC, Acta2/αSMA, TagIn/SM22α, and Mycdn/
myocardin was undetectable in both AdvSca1-SM and AdvSca1-MA progenitors (Figure 
3A). No difference in expression of SRF was detected among the cell populations (Figure 
3A). However, combined with loss of SRF binding to SM gene promoters by ChIP analysis 
(Supplemental Figure 7), these results suggest that the SMC differentiation program is 
repressed in AdvSca1-SM cells. In contrast to SM-specific genes, Klf4, the progenitor cell 
marker CD34, and progenitor cell-associated cytokines, VEGF and SDF-1α, were highly 
expressed in both populations of AdvSca1 cells compared to mature SMCs (Figure 3B). 
Finally, CD31, Flk-1, and Flt-1, commonly associated with endothelial/monocyte progenitor 
cells, were selectively expressed by AdvSca1-MA, but not AdvSca1-SM progenitor cells 
(Figure 3C) suggesting two distinct populations of AdvSca1 progenitor cells reside in the 
vessel wall.
We used flow cytometry to further immunophenotypically characterize these 
subpopulations. Two recent reports identified a population of non-hematopoietic-derived 
resident adventitial Sca1(+)CD45(+) macrophage progenitor cells5,26. Gated YFP(+) and 
YFP(−) cells (gating strategy shown in Supplemental Figure VIIIA) were analyzed for 
expression of CD45 and the common monocyte progenitor marker Ly6C to determine if 
CD45(+) macrophage progenitors reside selectively in the YFP(−) population. Whereas a 
much higher percentage of CD45(+) cells was identified in the YFP(−) cell fraction, the 
YFP(+) cell fraction was found to contain a small percentage of CD45(+) cells (Figure 
4A&F; Supplemental Table I). CD45(−) and CD45(+) cells from YFP(−) and YFP(+) 
populations were analyzed for Sca1 expression. Distinct populations of Sca1(+)CD45(−) and 
Sca1(+)CD45(+) were identified within both SMC-derived YFP(+) and non-SMC-derived 
YFP(−) cells (Figure 4B; Supplemental Table I). While the majority of Sca1(+)CD45(−) and 
Sca1(+)CD45(+) AdvSca1-MA progenitors also expressed Ly6C, only approximately half of 
Sca1(+)CD45(−) (54.6%) and Sca1(+)CD45(+) (56.1%) AdvSca1-SM progenitors 
expressed Ly6C (Figure 4C&F; Supplemental Table I). Ly6C(+) cells within the 
YFP(+)Sca1(+) and YFP(−)Sca1(+) populations co-expressed CD115, also a common 
monocyte progenitor marker (Figure 4D circled populations). Expression of the platelet 
derived growth factor receptors PDGF-Rβ/CD140b and PDGF-Rα/CD140a has been 
implicated in regulating a variety of progenitor cells and, in particular, specification of a 
SMC fate. CD31 is a cell surface marker expressed by a variety of cells, including mature 
endothelial cells and endothelial and myeloid progenitor cells. Compared to AdvSca1-MA 
cells, the vast majority of both CD45(−)Ly6C(+) and CD45(−)Ly6C(−) subpopulations of 
AdvSca1-SM cells expressed CD140b and CD140a (Figure 4E&F; Supplemental Table I; 
CD140b shown), but not CD31. In contrast, CD45(−)Ly6C(+) and CD45(−)Ly6C(−) 
subpopulations of AdvSca1-MA cells expressed either CD140b/CD140a or CD31; 
expression appeared to be mutually exclusive (Figure 4E&F; Supplemental Table I; CD140b 
shown). All non-SMC Sca1(+)CD45(+) cells were negative for CD140b, CD140a, and 
CD31 (Figure 4F; Supplemental Table I) whereas SMC-derived Sca1(+)CD45(+) cells either 
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expressed Ly6C and CD115 or CD140b and CD140a; none expressed CD31 (Figure 4F; 
Supplemental Table I). Finally, the remaining YFP(+)Sca1(−)CD45(−) population 
(Supplemental Figure VIIIB circled population in left panel) did not express the myeloid 
markers, Ly6C, CD115, or CD31 (Supplemental Figure VIIIB middle and right panels; 
CD115 not shown) and only expressed low levels of CD140b and CD140a (Supplemental 
Figure VIIIB right two panels; Supplemental Figure VIIIC) verifying this population as 
mature SMCs.
To determine if AdvSca1-SM cells possess multipotency potential capable of differentiating 
into other cell lineages, in vivo Matrigel™ plug angiogenesis assays were performed. 
AdvSca1-SM cells were recovered from SM22α-Cre-YFP mice, resuspended in Matrigel™ 
plus growth factors, subcutaneously injected into syngeneic wild type mice (WT) mice, and 
plugs examined 14 days post-implantation for SMC-, macrophage-, and endothelial cell-
specific markers (Myh11/SMMHC, F4/80, and von Willebrand factor [vWF], respectively). 
Analysis of YFP(+) cells demonstrated that AdvSca1-SM cells contribute to perivascular 
cells of functioning neovessels within Matrigel™ plugs that connected to the systemic 
circulation (Supplemental Figure IX). Many of these perivascular cells co-expressed 
SMMHC, a marker of differentiated SMCs (Figure 5A), demonstrating that AdvSca1-SM 
cells serve as SMC progenitor cells. In addition, we observed YFP(+)F4/80(+) cells largely 
in regions of the plug with recruited host-derived inflammatory cells demonstrating that 
AdvSca1-SM cells differentiate to macrophages (Figure 5B). Moreover, while the majority 
of endothelial cells in neovessels were host-derived (e.g. YFP−)(Supplemental Figure XA), 
YFP(+)vWF(+) endothelial-like cells were observed (Figure 5C and Supplemental Figure 
XB) supporting a role for AdvSca1-SM cells as endothelial cell precursors. Finally, 
undifferentiated YFP(+) cells still expressing Sca1 were observed surrounding newly 
developing vessels (Supplemental Figure XC). In vitro differentiation assays demonstrated 
the ability of SMC-derived AdvSca1 cells to also differentiate into adipocytes and 
chondrocytes (Supplemental Figure XI) thereby supporting the concept that AdvSca1-SM 
cells exhibit a multipotent progenitor cell phenotype. Collectively, these data suggest that 
differentiated SMCs can generate distinct subpopulations of multipotent progenitor cells that 
reside in the vascular adventitia.
AdvSca1-SM cells expand in number in response to vascular injury
While the predominant focus of the vascular response to injury has been on neointima 
formation and vessel occlusion, previous reports have also demonstrated early activation and 
expansion of adventitial cells following injury43–46. To determine if AdvSca1-SM cells 
contribute to adventitial cell expansion early after vascular injury, carotid artery ligation 
injuries were performed on 2-mo old SM22α-Cre-YFP mice. Compared to uninjured 
contralateral controls (Supplemental Figure XIIA&B), there was a large increase in the 
numbers of YFP+αSMA− adventitial cells 3 days post injury (Figure 6A and Supplemental 
Figure XIIC). While this consisted of increases in both Sca1+YFP+ and Sca1−YFP+ 
adventitial cells, the majority of YFP+ adventitial cells co-expressed Sca1 (Figure 6B,E). 
Similarly, there were increased numbers of CD45+YFP+ and CD45−YFP+ adventitial cells 
in response to injury. Although rare in uninjured vessels, SMC-derived CD45+ adventitial 
cells increased in response to injury; the majority of CD45+ adventitial cells, however were 
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YFP− non-SMC-derived (Figure 6C,D,F). These data are consistent with the concept that 
resident vascular progenitor cells, and in particular SMC-derived AdvSca1 cells, are 
activated early and are the dominant source of adventitial remodeling in response to vascular 
injury.
SMC generation of AdvSca1-SM cells is dependent on induction of Klf4
While many somatic cells, including SMCs, have been successfully reprogrammed in vitro 
to iPS cells using exogenous approaches47, endogenous mechanisms directing 
reprogramming are largely undefined. Klf4, a Kruppel-like transcription factor member, is 
not expressed in differentiated SMCs (Figure 3), but its induction contributes to SMC 
phenotypic switching48. Klf4 has been shown to be one of four genes necessary for in vitro 
iPS cell generation, underscoring its importance in maintenance of a progenitor cell 
phenotype49. Since Klf4 was highly expressed by AdvSca1-SM cells (Figure 3 and 
Supplemental Figure 6), we examined its role in SMC generation of AdvSca1-SM cells. To 
determine if induction of Klf4 in differentiated SMCs was required in vivo, aortas from 8–
10-day old WT and SMC-specific Klf4-deficient mice (SM22α-CreKI-YFP Klf4 SM-KO) 
were examined for the presence of AdvSca1 cells. We found abundant numbers of 
adventitial Sca1+ cells in WT mice (Figure 7A). In contrast, adventitial Sca1+ cells were 
barely detectable in aortae from SM22α-CreKI-YFP Klf4 SM-KO mice (Figure 7B). FACS 
analysis was used to quantitate AdvSca1-SM and AdvSca1-MA cells in WT and Klf4 SM-
KO mice. No difference in the numbers of AdvSca1-MA cells was observed, as anticipated 
since Klf4 was not deleted from non-SMC-derived cells (Figure 7D). Compared to WT 
mice, however, decreased numbers of AdvSca1-SM cells was confirmed in carotid arteries 
plus aortic arch and descending aortae of Klf4 SM-KO mice (Figure 7C) supporting the 
concept that Klf4 induction is necessary for SMCs to generate progenitor cells. 
Unfortunately, due to premature death of SM22α-CreKI-YFP Klf4 SM-KO mice by 4 wks 
of age (our unpublished observations and 50), we were unable to demonstrate the biological 
importance of Klf4 in the expansion of AdvSca1-SM cells after vascular injury. To test if 
Klf4 is sufficient to promote a progenitor cell phenotype as defined by expression of 
progenitor cell markers and repression of SM genes, cultured SMCs were transduced with 
adenoviruses expressing GFP (control) or Klf4-GFP. By FACS analysis, we observed 
approximately 50% transduction efficiency (Supplemental Figure XIIIA). Compared to 
GFP-transduced SMCs, Klf4-transduced SMCs expressed increased levels of cell surface 
Sca1 and CD34 (Supplemental Figure XIIIB&C). This was associated with downregulation 
of SMC-specific markers at the level of mRNA and protein (Supplemental Figure 
XIIIC&D).
We previously demonstrated that Klf4 is downregulated as AdvSca1 cells differentiate in 
culture and acquire SMC markers4. Based on its known function as a co-repressor of SRF-
dependent SMC gene transcription and as a regulator of self-renewal in embryonic stem 
cells, we sought to determine if Klf4 is critical for maintenance of a progenitor cell 
phenotype. We used in vitro approaches to silence Klf4 using control non-targeting or Klf4-
specific siRNAs or overexpress Klf4 using adenoviruses expressing empty vector (control) 
or wild type Klf4. Compared to control siRNA, Klf4 knockdown decreased Sca1 mRNA 
expression (Supplemental Figure XIVA) and reduced the number of Sca1-positive cells, as 
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evaluated by immunofluorescence staining (Figure 8A&B left). This was associated with a 
trend toward an increased fraction of cells exhibiting αSMA-positive contractile filaments 
(Figure 8A&B right) suggesting that loss of Klf4 accelerates differentiation of AdvSca1 
cells toward a SMC fate. In contrast to Klf4 silencing, adenoviral-mediated over-expression 
of Klf4 resulted in increased Sca1 expression and decreased αSMA expression 
(Supplemental Figure XIVB). This was associated with increased numbers of Sca1-positive 
cells (Figure 8C&D left) and blocked the differentiation of AdvSca1 cells to SMCs, as 
measured by decreased fraction of cells exhibiting αSMA-positive contractile filaments 
(Figure 8C&D right). Collectively, these data are consistent with an essential role for Klf4 in 
SMC reprogramming, similar to a recent report31, and in the maintenance of the AdvSca1 
progenitor phenotype.
DISCUSSION
In previous experiments to determine the fate of medial SMCs in injured arteries, we made 
the entirely unexpected observation that some mature SMCs migrate from the media into the 
adventitia, and become SMC marker negative33. In this report, using two independent SMC 
genetic fate-mapping systems combined with a SMC lineage-specific chromatin mark, we 
demonstrate that SMCs moving into the adventitia gain expression of progenitor cell 
markers (Sca1, CD34, Klf4) and become residents within the adventitial progenitor niche 
that we and others have described2, 4, 5. We propose that this phenomenon is a type of in situ 
SMC reprogramming with the evidence to support this as follows: (1) no detectable SMC 
differentiation marker expression by AdvSca1-SM cells, (2) no detectable binding of SRF to 
CArG elements in SMC marker gene promoter regions in these cells, (3) loss of the H4Ac 
differentiation-associated mark on SMC promoter CArG elements by AdvSca1-SM cells, 
but (4) retention of the H3K4Me2 SMC lineage mark, (5) gain of expression of functional 
progenitor marker genes by AdvSca1-SM cells, and (6) gain of multipotential fate 
capabilities as defined by differentiation in vivo into SMCs, macrophages, and endothelial 
cells. Further study showed that SMC-derived progenitor cells reside in the adventitia of 
aortic arch and carotid arteries, descending aorta, and femoral arteries, each from distinct 
embryonic lineages, in numbers representing approximately 60%, 40%, and 30%, 
respectively, of the total adventitial Sca1+ progenitor cell population of these vessels. Taken 
together, our data suggest the novel possibility that during vascular development 
differentiated SMCs migrate from the outer media into the inner adventitia where they 
become reprogrammed to a progenitor-like state. Since formation of AdvSca1-SM cells was 
observed in adult mice after treatment with tamoxifen, this would also suggest SMC 
reprogramming is a continual process likely serving as a mechanism to replace resident 
vascular progenitor cells. This activity would be similar, in principle, to the reversion of 
mature differentiated cells to fate-restricted progenitor cells in regeneration of tracheal cell 
types following lung injury51 and stomach crypt cells in response to stem cell ablation52. An 
important difference and the novel aspect of our findings, however, is that our data support 
the concept that formation of AdvSca1-SM cells from mature SMCs is a normal 
physiological process, in contrast to these previous studies in which differentiated cells 
revert to progenitor cells only in the setting of experimental tissue injury or stem cell 
ablation. We are aware that Myh11/SMMHC can sometimes be expressed by microvascular 
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pericytes and that some myeloid and myofibroblastic cells express Acta2/αSMA and Tagln/
SM22α (but not Myh11). At this time, we cannot rule out the possibility that some of the 
AdvSca1-SM cells we identify here may have an origin from adventitial cells. However, 
vasa vasorum microvessels are sparse in normal murine adventitia and a substantial origin of 
AdvSca1-SM cells from these alternate sources seems unlikely.
While remodeling of the adventitia has been known to occur following many forms of 
vascular injury, it is widely assumed that medial SMCs do not directly participate in this 
response. This is likely due to the vast majority of studies in the literature that identify 
SMCs in injured arteries by their expression of conventional SM marker proteins (eg. Acta2/
αSMA, Myh11/SMMHC). By those criteria, intimal SMCs, many plaque macrophages31,34, 
and AdvSca1-SM cells, which lose expression of these markers, would not be recognized as 
SMC-derived. Recent advances in SMC fate-mapping systems that permanently mark 
mature SMCs has allowed reliable identification of these cells as SMC-derived even if they 
lose all characteristics of SMCs. Using these systems, our data (Supplemental Figure I) and 
recent reports by others31, 34 have conclusively demonstrated that the percentage of SMCs 
contributing to intimal lesion formation and atherosclerosis is much greater than previously 
estimated from expression of traditional SMC markers. While the mechanisms regulating 
SMC migration into the adventitia remain unclear, it is well known that breaks in the internal 
elastic lamina facilitate migration of SMCs into the intima. We assert that it would not be 
completely unexpected that breaks in the external elastic lamina, as observed during vascular 
development and following injury to the vessel wall, would result in a similar movement of 
SMCs into the adventitia. Our ongoing studies are addressing this possibility in more detail.
From their earliest description, it was evident that the AdvSca1-positive cell population in 
the aortic adventitia was heterogeneous. For example, Hu et. al.2 reported that Sca1-positive 
cells isolated from the aortic root adventitia of adult ApoE−/− mice contained ~60% 
fibroblastic cells, ~20% epithelioid cells, and occasional adipocyte-like cells. Passman et. 
al. 4, Rev. in 16 found that about 50% of freshly isolated aortic AdvSca1 cells from wild type 
C57Bl/6 mice lost Sca1 expression and differentiated into SMC marker-positive cells over 8 
days ex vivo, while ~25% proliferated as Sca1-positive cells without SMC differentiation, 
and the remaining 25% lost expression of Sca1 but did not acquire detectable levels of SMC 
marker expression. Psaltis et. al.5 found that aortic cells isolated from wild type C57Bl/6 
mice exhibited hematopoietic colony forming activity predominantly for progenitors 
expressing a macrophage fate. Further study showed that co-expression of Sca1 and CD45 in 
the adventitia marked the CFU-M progenitor cells and these Sca1+/CD45+ cells comprised 
about 36% of the total aortic Sca1-positive cell population21. The remaining Sca1+/CD45− 
cell population was shown in previous studies to possess SMC differentiation potential 
without hematopoietic colony forming activity2, 4. Our results reported in the present study 
confirm and extend this prior work supporting the concept that the aortic adventitia contains 
at least two types of AdvSca1 progenitor cells. Based on expression of cell surface markers, 
our data suggest that SMC-derived AdvSca1 cells express predominantly a myogenic 
progenitor phenotype (AdvSca1-SM) whereas non-SMC-derived AdvSca1 cells express 
predominantly a macrophage progenitor cell phenotype (AdvSca1-MA). However, 
myogenic and macrophage progenitor cell phenotypes were observed within subpopulations 
of both the AdvSca1-SM and AdvSca1-MA populations supporting the likelihood of 
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multipotent fate decisions. Indeed, our in vivo Matrigel™ plug assays and in vitro 
differentiation assays demonstrated the ability of AdvSca1-SM cells to differentiate into 
SMCs, macrophages, endothelial-like cells, adipocytes, and chondrocytes further supporting 
the multipotency of these cells.
Induction of pluripotent stem cells from somatic cells can be accomplished through forced 
overexpression of the transcription factors, Oct-4, Sox2, Klf4, and c-Myc49. Our current and 
previous4 results together with our unpublished RNA-Seq data demonstrate high expression 
levels of Klf4 and Myc/c-Myc, but not POU5F1/Oct4 or Sox2, in both populations of 
AdvSca1 cells further suggesting that these cells possess a fate-restricted multipotent, but 
not pluripotent phenotype. This would be similar to the detection of fate-restricted 
progenitor cells during regeneration of axolotl limb53, zebrafish fin54, mouse digit tip55, 56, 
and both zebrafish57 and neonatal mouse58 hearts after apex amputation injury. Further, our 
finding that the AdvSca1-SM subset arises predominantly from pre-existing SMCs offers an 
explanation for the previously puzzling observation that despite being SMC marker-
negative, AdvSca1 cells express a transcription factor profile typically found in mature 
SMCs4. Our findings suggest very little contribution of AdvSca1-SM cells to the previously 
identified CFU-M subset5, 26. However, our findings suggest that AdvSca1-SM CD45+ cells 
contribute to the adventitial myeloid cell population, which is consistent with differentiation 
of AdvSca1-SM cells into macrophages as observed in in vivo Matrigel™ plug assays, and to 
expansion of adventitial CD45+ cells following vascular injury.
The adventitia is a complex layer of the vessel wall than previously thought that responds 
rapidly and robustly to many forms of arterial injuryRev. in 17. Previous studies point to the 
adventitial fibroblast as the main responders to vessel injury. For instance, Shi, et. al.43 and 
Scott, et. al.44 reported that adventitial cells, referred to as fibroblasts, proliferated earlier 
and to a greater extent than medial SMCs in response to balloon arterial injury. Our data 
demonstrate that AdvSca1-SM, in particular, are robustly activated and expand considerably 
in numbers early after arterial injury. Mobilization of AdvSca1-SM cells might participate in 
medial repair by differentiating into medial SMCs, and/or in neointimal formation. We 
propose that AdvSca1-SM progenitor cells may also play major roles during injury-mediated 
adventitial remodeling. In support of this model, and in agreement with our data, a recent 
report demonstrates that AdvSca1 cells are major sources of angiotensin II-induced 
adventitial fibrosis leading to artery wall stiffening and hypertension59. Similarly, using the 
mdx mouse model of Duchenne muscular dystrophy, Ieronimakis et. al.60 found that the 
major collagen-producing cell type associated with late onset cardiac fibrosis was the 
coronary AdvSca1 cell. Ongoing studies using fate-mapping approaches to selectively label 
SMC-derived AdvSca1-SM cells are addressing these possibilities.
The pluripotency-associated transcription factor, Klf4, is also well known to regulate SMC 
phenotypic changes and multiple lines of evidence support an important role for Klf4 in 
vascular disease progression31, 48,. Using in vivo and in vitro approaches, our studies 
establish that SMC generation of AdvSca1-SM cells is dependent on induction of Klf4. In 
vivo targeted deletion of the Klf4 gene in SMCs resulted in selective loss of AdvSca1-SM 
cells, but not AdvSca1-MA cells suggesting that failure to induce Klf4 prevents AdvSca1-
SM cell generation from SMCs and establishment of this subpopulation of resident AdvSca1 
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cells. In support of these in vivo findings, overexpression of Klf4 in cultured SMCs 
promoted a progenitor cell phenotype as defined by loss of SMC differentiation markers and 
gain of progenitor cell markers. Unfortunately, early postnatal death of SMC-specific Klf4 
SM-KO mice precluded our ability to define the biological importance of Klf4 on expansion 
of AdvSca1-SM cells in response to vascular injury. We recognize that, compared to WT 
mice, AdvSca1-SM cell numbers decreased in SMC-specific Klf4 KO mice by only 50%. 
This is likely due to the late developmental activation of Cre recombinase and thus SMC 
deletion of Klf4 in SM22α-CreKI compared to SM22α-Cre mice61. If migration into the 
adventitia and reprogramming occurred prior to Cre activation and inactivation of KLF4 in a 
subset of SMCs, the potential for Klf4 to be induced and promote AdvSca1-SM cell 
generation in this subset would remain. Finally, loss- and gain-of-function studies 
demonstrated that Klf4 is critical for the maintenance of the AdvSca1 progenitor cell 
phenotype. Collectively, our data demonstrate that Klf4 is a critical regulator of AdvSca1-
SM cell generation and maintenance of the resident vascular progenitor cell pool.
In summary, our findings suggest that the local environment of the inner adventitia directs or 
stabilizes a Klf4-dependent SMC reprogramming-like process to maintain a vascular 
progenitor cell pool in the artery wall. Depending on environmental cues, SMC-derived 
progenitor cells may express cell fates resembling tissue resident macrophages, mural cells, 
endothelial-like cells, adipocytes, and osteoblasts. Going forward, the identification of 
factors in addition to Klf4 that regulate SMC-to-progenitor cell transitions in vivo will 
broaden our understanding of the multiple roles SMCs play in vascular homeostasis and 
disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank Radu Moldovan and Greg Glazner of the UCD Advanced Microscopy Core Facility for assistance with 
confocal microscopy and Karen Helm and staff of the UC Cancer Center Flow Cytometry Core Facility.
SOURCES OF FUNDING
This work was funded by grants from the National Heart, Lung, and Blood Institute of the National Institutes of 
Health to MCMW-E (R21 HL114126, R01 HL121877, and R01 HL123650) and MWM (R01 HL123650 and R01 
HL121877), and from the American Heart Association to JNR and MWM (AHA 0715320U). The University of 
Colorado Cancer Center Flow Cytometry Core Facility is funded through a support grant from the National Cancer 
Institute (P30 CA046934). Imaging experiments were performed in the University of Colorado Anschutz Medical 
Campus Advanced Light Microscopy Core supported in part by NIH/NCATS Colorado CTSI Grant Number UL1 
TR001082.
Nonstandard Abbreviations and Acronyms
SMCs smooth muscle cells
AdvSca1 adventitial sca1-positive progenitor cells
Sca1 stem cell antigen-1
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Shh sonic hedgehog
SRF serum response factor
Mhy11/SMMHC smooth muscle myosin heavy chain
Acta2/αSMA smooth muscle-α-actin
Tmx tamoxifen
Dpp days post-partum
AdvSca1-MA non-SMC-derived AdvSca1(+) cells
AdvSca1-SM SMC-derived AdvSca1(+) cells
ChIP chromatin immunoprecipitation
qPCR quantitative polymerase chain reaction
iPS induced pluripotent stem cell
Klf4 kruppel-like factor 4
Cre Cre recombinase
WT wild type
KO knockout
FACS fluorescence-activated cell sorting
YFP yellow fluorescent protein
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Novelty and Significance
What Is Known?
• Multipotent vascular progenitor cells expressing stem cell markers Sca1 and 
CD34 (AdvSca1 cells) reside in a unique niche in the inner adventitia of 
several vascular beds.
• Using bone marrow transplant and adoptive transfer approaches, it has been 
shown that AdvSca1 cells do not originate from bone marrow or circulating 
cells.
• AdvSca1 progenitor cells appear late during vascular development after the 
arterial media is fully formed, vascular smooth muscle cells (SMCs) have 
acquired a differentiated phenotype, and layering of the vessel wall has 
stopped.
What New Information Does This Article Contribute?
• Differentiated SMCs in the outer media migrate into the inner adventitia and 
lose expression of SMC markers, gain expression of progenitor cell markers, 
and contribute to a subpopulation of AdvSca1 progenitor cells.
• SMC-derived AdvSca1 cells can differentiate to mural cells, macrophage-like 
cells, and endothelial-like cells within Matrigel™ implants in vivo. They can 
also give rise to adipocytes and chondrocytes under defined in vitro 
conditions at lower frequencies.
• Formation and maintenance of AdvSca1 cells from SMCs is dependent on 
induction of the pluripotency-associated transcription factor, Kruppel-like 
factor 4 (KLF4).
The vascular adventitia is a complex layer of the vessel wall containing populations of 
leukocytes, microvessels, and resident progenitor cells that collectively maintain the 
artery wall and respond robustly to arterial injury. Factors governing the cell composition 
of the adventitia are expected to contribute to the health and maintenance of blood vessels 
and the tissues and stem cell populations they support. Identification and characterization 
of resident vascular progenitor cells might have significant therapeutic implications in 
vascular diseases and regenerative medicine. We show that differentiated SMCs migrate 
from the arterial media into the adventitia and revert to multipotent vascular progenitor 
cells through a physiological reprogramming-like process. Depending on environmental 
cues, SMC-derived progenitor cells may adopt cell fates resembling tissue resident 
macrophages, mural cells, endothelial cells, adipocytes, and osteoblasts. SMC 
reprogramming is dependent on induction of the transcription factor, KLF4. Moving 
forward, identification of additional factors regulating the SMC-to-progenitor cell 
transition in vivo is expected to broaden our understanding of the multiple roles SMCs 
play in vascular homeostasis and disease. Manipulations of these cells in situ might have 
therapeutic applications in settings such as atherosclerosis/restenosis, aneurysm, 
ischemia, and tumor angiogenesis.
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Figure 1. SMC-derived adventitial cells express stem cell markers
Two-month old Myh11-CreERT-βGal or -YFP mice received I mg IP tamoxifen injections 
once a day for five consecutive days. Aortae, carotid arteries plus aortic arch, and femoral 
arteries were harvested 8-weeks post-tamoxifen. (A). Aortas were whole mount stained for 
X-Gal; histological section from a representative aorta showing βGalactosidase activity 
(blue reaction color). Arrows = X-Gal-positive SMC-derived adventitial cell. Arrowheads = 
external elastic lamina. Dashed line represents media-adventitia boundary. (B–E). Carotid or 
femoral arteries were immunofluorescently stained for αSMA (red) and YFP (green; B), 
Sca1 (red) and YFP (green; C&D), or CD34 (red) and YFP (green; E). Representative 
carotid arteries are shown in (B,C,&E); representative femoral artery shown in (D). Arrow = 
SMC-derived adventitial cells. A = adventitia; M = media. Dashed lines represent media-
adventitia boundary. (F&G). Higher magnification images of inset boxes in (B&C). Scale 
bars=50μm. A minimum of 8 mice were analyzed.
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Figure 2. Percentage of total AdvSca1 cells originating from differentiated SMCs
(A). Carotid arteries (CA) plus aortic (Ao) arch, descending aorta, and femoral arteries were 
harvested from two-month old SM22α-Cre-YFP mice. Arteries from 5–7 mice were pooled, 
digested into single cell suspensions, labeled with an APC-conjugated anti-Sca1 antibody, 
and flow sorted based on endogenous YFP and Sca1 expression. The percent±SE SMC-
derived YFP(+)Sca1(+) (quadrant B; Supplemental Figure 5) of total Sca1(+) cells 
(quadrants A + B; Supplemental Figure 5) from 7 independent sorts is shown in the table. 
(B). Representative immunofluorescent stains of carotid artery sections from two-month old 
SM22α-Cre-YFP mice for αSMA (red) and YFP (green; top panels), Sca1 (red) and YFP 
(green; middle panels), or CD34 (red) and YFP (green; bottom panels). Arrows = YFP(+) 
adventitial cells. Dashed lines represent media-adventitia boundary. A minimum of 8 mice 
were analyzed. Scale bars=50μm. (C). Higher magnification image of inset box in (B, 
middle panel). (D). Representative immunofluorescent stain of a carotid artery section from 
a five day-old SM22α-Cre-YFP mouse for YFP (green), Sca1 (red), and αSMA (white). 
Arrows = SMC-derived AdvSca1+ cells expressing residual levels of αSMA; Arrowheads = 
SMC-derived adventitial cells expressing residual levels of αSMA and low/absent levels of 
Sca1. Dashed line represent media-adventitia boundary. Scale bars=50μm.
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Figure 3. Progenitor cell marker expression in AdvSca1 cells
Total RNA was isolated from cell populations from pooled, digested arteries from SM22α-
Cre-YFP mice and analyzed by qPCR for the indicated mRNAs. Shown are fold changes in 
mRNA copy number±SE from an N=3 independent experiments using arteries from 10 
pooled mice per experiment; *P<0.05. β-actin was used for normalization. (A). SMC 
markers. To compare among individual experiments, data was normalized to YFP(+) SMCs. 
(B). Progenitor cell markers expressed by both Sca1+ populations. To compare among 
individual experiments, data was normalized to AdvSca1-MA cells. (C). mRNAs selectively 
expressed in Sca1(+)YFP(−) cells. To compare among individual experiments, data was 
normalized to AdvSca1-MA cells. Shown for all panels are data obtained from cell 
populations isolated from pooled carotid arteries plus aortic arch. ND = not detectable.
Majesky et al. Page 22
Circ Res. Author manuscript; available in PMC 2018 January 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. FACS profiling reveals distinct subpopulations of AdvSca1 cells
Single cell suspensions were obtained from digested arteries from SM22α-Cre-YFP mice. 
(A). Representative flow cytometry plots showing expression of CD45 and Ly6C in YFP(−) 
and YFP(+) cells. (B). Representative flow cytometry plots showing expression of Sca1 in 
CD45(−) and CD45(+) cells from YFP(−) and YFP(+) cell populations. (C). Representative 
flow cytometry plots showing expression of Ly6C in Sca1(+)CD45(−) and Sca1(+)CD45(+) 
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cells from YFP(−) and YFP(+) cell populations. (D). Representative flow cytometry plots 
showing expression of Ly6C and CD115 in YFP(−) and YFP(+) cells. (E). Representative 
flow cytometry plots for expression of CD140b and CD31 in Sca1(+)CD45(−)Ly6C(−) and 
Sca1(+)CD45(−)Ly6C(+) cells from YFP(−) and YFP(+) cell populations. (F). Pie charts 
illustrating the various subpopulations of Sca1(+) progenitor cells within Sca1(+)YFP(−) 
and Sca1(+)YFP(+) groups. Shown for all are data obtained from cell populations isolated 
from carotid arteries plus aortic arch; N=4 independent analyses using pooled arteries from 5 
mice.
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Figure 5. AdvSca1-SM cells exhibit multipotency potential
AdvSca1-SM cells were isolated from SM22α-Cre-YFP mice by flow sorting, embedded in 
Matrigel™, and subcutaneously implanted into syngeneic WT mice. Matrigel™ plugs were 
harvested 14 days post-implantation for immunofluorescence analysis. (A). Representative 
stains of neovessels within plugs for YFP (green) and the SMC-specific marker, SMMHC 
(red). (B). Representative stains for YFP (green) and the macrophage-specific marker, F4/80 
(red). (C). Representative stain of an endothelial cord for YFP (green) and the endothelial 
cell-specific marker, von Willebrand Factor (vWF)(red). Arrows = AdvSca1-SM-derived 
endothelial cells. Scale bars=50μm. N=4 independent analyses.
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Figure 6. Injury-induced expansion of AdvSca1-SM cells
Two-month old SM22α-Cre-YFP mice were subjected to carotid artery ligation injury and 
injured left and uninjured right arteries were harvested 3-days post injury for 
immunofluorescence analysis. (A). Representative stains of injured vessels for αSMA (red) 
and YFP (green) from 2 independent mice showing expansion of SMC-derived adventitial 
cells. (B). Representative stain of an injured vessel for Sca1 (red) and YFP (green). (C). 
Representative stain of an injured vessel for CD45 (red) and YFP (green). Arrows = 
YFP(+)CD45(+) adventitial cells. M = arterial media; A = arterial adventitia; arrowheads = 
internal (A) and external elastic laminae. (D). Higher magnification images of arrows in 
panel (C). For A–C, dashed lines represent media-adventitia boundary. (E&F). Total 
numbers of adventitial Sca1(−)YFP(+), Sca1(+)YFP(+), or Sca1(+)YFP(−) cells (panel E) or 
CD45(−)YFP(+), CD45(+)YFP(+), or CD45(+)YFP(−) cells (panel F) in uninjured 
compared to injured arteries were quantitated as described in Material and Methods. Total 
numbers±SE are recorded in the graphs. N=3 independent mice; *P<0.05. Scale bars=50μm.
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Figure 7. SMC reprogramming is dependent on Klf4 induction
Aorta and carotid arteries plus aortic arch were harvested from 8–10-day old SM22α-CreKI-
YFP WT (A) or SM22α-CreKI-YFP Klf4 KO (B) mice. Representative immunofluorescent 
stains of aortic sections for Sca1 (red) and YFP (green); aortae from two independent WT 
and KO mice shown; N=6 per genotype total. Scale bars=50μm. Dashed lines represent 
media-adventitia boundary. (C&D). FACS analysis was used to quantitate SMC-derived 
AdvSca1-SM (C) or non-SMC-derived AdvSca1-MA (D) cells in WT versus Klf4 KO mice. 
Each symbol represents data from an individual mouse. N=7 WT and N=5 KO mice.
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Figure 8. Klf4 maintains the progenitor phenotype
(A&B). Isolated AdvSca1 cells from WT mice were cultured for 24 h, transfected with 
siRNAs targeting GFP (control) or KLF4, and evaluated 72 hrs after siRNA transfection. (A) 
Representative images from treated cultures with immunostaining for αSMA (green), Sca1 
(red), and DAPI (blue). Sca1-positive and αSMA-positive cells from each treatment group 
were counted and normalized to total cell numbers. N=3 independent experiments; *P<0.05. 
(C&D). Isolated AdvSca1 cells from WT mice were transduced with an empty adenovirus 
(control) or a Klf4-expressing adenovirus then cultured for 7 days. (C) Representative 
images from treated cultures with immunostaining for αSMA (green), Sca1 (red), and DAPI 
(blue). (D) Sca1-positive and αSMA-positive were counted and normalized to total cell 
numbers. N=3 independent experiments; *P<0.05.
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